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New treatments are needed for severe asthmatics to improve disease control and avoid
severe toxicities associated with oral corticosteroids. We have used a murine model of
house dust mite (HDM)-induced asthma to identify steroid-unresponsive genes that might
represent targets for new therapeutic approaches for severe asthma. This strategy iden-
tiﬁed apolipoprotein E as a steroid-unresponsive gene with increased mRNA expression
in the lungs of HDM-challenged mice. Furthermore, apolipoprotein E functioned as an
endogenous negative regulator of airway hyperreactivity and goblet cell hyperplasia in
experimental HDM-induced asthma. The ability of apolipoprotein E, which is expressed
by lung macrophages, to attenuate AHR, and goblet cell hyperplasia is mediated by low
density lipoprotein (LDL) receptors expressed by airway epithelial cells. Consistent with
this, administration of an apolipoprotein E mimetic peptide, corresponding to amino acids
130–149 of the LDL receptor-binding domain of the holo-apoE protein, signiﬁcantly reduced
AHR and goblet cell hyperplasia in HDM-challenged apoE−/− mice.These ﬁndings identiﬁed
the apolipoprotein E – LDL receptor pathway as a new druggable target for asthma that
can be activated by administration of apoE-mimetic peptides. Similarly, apolipoprotein A-I
may have therapeutic potential in asthma based upon its anti-inﬂammatory, anti-oxidative,
and anti-ﬁbrotic properties. Furthermore, administration of apolipoprotein A-I mimetic pep-
tides has attenuated airway inﬂammation, airway remodeling, and airway hyperreactivity in
murine models of experimental asthma.Thus, site-directed delivery of inhaled apolipopro-
tein E or apolipoprotein A-I mimetic peptides may represent novel treatment approaches
that can be developed for asthma, including severe disease.
Keywords: asthma, apolipoprotein E, apolipoprotein A-I, apolipoprotein E mimetic peptide, apolipoprotein A-I
mimetic peptide
WHY ARE NEW TREATMENTS NEEDED FOR PATIENTS WITH
SEVERE ASTHMA?
Severe asthma is a major public health and economic problem.
The World Health Organization1 estimates that approximately
235 million people worldwide suffer from asthma. Although less
than 5% of asthmatics have severe disease, they account for
approximately 50% of all the direct and indirect costs associated
with asthma (Braman, 2006). The deﬁnition of severe, refractory
asthma, as determined by the American Thoracic Society, is the
need for either continuous or near continuous oral corticosteroids
for more than 50% of the year and/or high-dose inhaled corticos-
teroids to achieve control to a level similar to patients with mild or
moderate persistent asthma (American Thoracic Society, 2000).
The deﬁnition of severe, refractory asthma also requires two or
more of the following; daily treatment with a controller medica-
tion in addition to inhaled corticosteroids, daily or near daily need
for short-acting β-agonist to control asthma symptoms, persistent
airﬂow obstruction (FEV1< 80% predicted), one or more urgent
1http://www.who.int/mediacentre/factsheets/fs307/en/index.html
care visits for asthma per year, three of more oral steroid “bursts”
per year, prompt decline in asthma control with ≤25% reduction
in oral or inhaled corticosteroid dose, or near fatal asthma event
in past (American Thoracic Society, 2000). Consistent with this
deﬁnition, severe asthmatics, as compared to those with mild or
moderate asthma, are more likely to be older with a longer dura-
tion of disease, have more daily symptoms, have increased rates of
urgent health care utilization, have more sinusitis and pneumo-
nia, are less atopic, and have lower lung function with increased
gas trapping and bronchodilator reversibility (Moore et al., 2007;
Sorkness et al., 2008).
Limited treatment options are available for severe asthmat-
ics. The most recent NHLBI National Asthma Education and
Prevention Expert Panel 3 Report recommends that severe asth-
matics be treated with high doses of an inhaled corticosteroid
plus a long-acting beta2-agonist (LABA) and oral corticosteroids.
Omalizumab, an anti-IgE monoclonal antibody, can reduce the
frequency of asthma exacerbations and the dose of inhaled corti-
costeroids in severe, allergic asthmatics whose serum IgE levels fall
within the target range (Fanta, 2009). Limitations regarding oma-
lizumab are that it requires parenteral administration, is expensive
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and can infrequently be associated with anaphylaxis in 0.1% of
patients (Strunk and Bloomberg, 2006). Bronchial thermoplasty
is a new treatment option that requires several bronchoscopies to
deliver thermal energy that ablates airway smooth muscle (Castro
et al., 2010). The U.S. Food and Drug Administration has recently
approved this procedure for adult asthmatics who have persis-
tent symptoms despite inhaled corticosteroids plus LABAs. There,
however, remains an unfulﬁlled need for the development of addi-
tional new treatment options for severe asthma that improve
disease control, are cost–effective and can spare patients from
the potentially devastating side-effects related to chronic corti-
costeroid therapy, but do not require parenteral administration or
an invasive procedure.
BENCH-TO-BESIDE: USING A MURINE MODEL OF HOUSE
DUST MITE-INDUCED ASTHMA TO IDENTIFY
STEROID-UNRESPONSIVE GENES THAT MAY MODULATE
ASTHMA PATHOGENESIS AND DISEASE SEVERITY
Although corticosteroids can improve symptom control in severe
asthmatics, chronic administration can be associated with debili-
tating side-effects, which include diabetes, aseptic bone necrosis,
weight gain, hypertension, and impaired host defense. Therefore,
severe asthmatics who require chronic oral corticosteroids fre-
quently seek an alternative medication that will allow a reduction,
or ideally a discontinuation, of chronic oral corticosteroid therapy.
Furthermore, patients with severe asthma or asthmatics who
smoke cigarettes may be poorly responsive or completely resis-
tant to corticosteroids based upon the presence of glucocorti-
coid resistance due to a decrease in histone deacetylase 2 activ-
ity or reduced nuclear translocation of glucocorticoid receptors
(Barnes, 2011). We reasoned that there might exist differentially
expressed genes in asthmatic lungs that are up-regulated in the
setting of asthma and remain persistently up-regulated despite
treatment with corticosteroids. Furthermore, we considered that
these steroid-unresponsive genes might modulate the pathogen-
esis of asthma and represent novel therapeutic targets for the
development of new asthma medications.
To identify these steroid-unresponsive genes, we utilized a
murine model of house dust mite (HDM)-induced airway
inﬂammation, airway remodeling, and airway hyperreactivity. We
selected HDM because it is a common aeroallergen that is an
environmental trigger and risk factor for the development of per-
sistent asthma (Sears et al., 2003; Johnson et al., 2004). HDM
is a complex mixture of proteins and lipopolysaccharide (LPS)
that induces airway inﬂammation via allergic and non-allergic
mechanisms (Thomas et al., 2002; De Alba et al., 2009; Lambrecht
and Hammad, 2009). We proposed that genes could be identi-
ﬁed whose expression is up-regulated in the lung in response to
HDM challenge and remain greater than twofold up-regulated
despite treatment with corticosteroids as compared to control
saline-challenged mice. This scenario simulates a patient who
presents to their health care providerwith persistent asthma symp-
toms despite treatment with high doses of inhaled or oral corti-
costeroids. Furthermore, we reasoned that these corticosteroid–
unresponsive genes might provide mechanistic insights into the
pathogenesis of asthma and potentially represent new therapeutic
targets that could be relevant for the treatment of severe asthma.
Wild-type A/J mice, which have enhanced susceptibility to the
induction of asthma and allergen-mediated airway hyperreactiv-
ity, received saline, or HDM by nasal administration 5 days per
week for 6weeks (Levitt andMitzner, 1988;Wills-Karp and Ewart,
1997; Finkelman et al., 2010). Dexamethasone (1mg/kg) or saline
was administered via an osmotic mini-pump during weeks four
through six to simulate treatment of established asthma (Yao et al.,
2010). We found that corticosteroid treatment dissociated air-
way hyperreactivity from airway inﬂammation and goblet cell
hyperplasia in this experimental murine model of HDM-induced
asthma (Yao et al., 2010).While corticosteroid administration was
very effective at suppressing airway inﬂammation and goblet cell
hyperplasia, it resulted in only a small, but statistically signiﬁ-
cant, decrease in airway hyperreactivity that remained increased
as compared to control mice. This ﬁnding is consistent with prior
murine and human studies, which showed that airway inﬂamma-
tion and airway hyperreactivity, are mediated by distinct pathways
that may be uncoupled (Crimi et al., 1998; Swedin et al., 2009).
Thus, administration of dexamethasone toHDM-challengedmice
generated a steroid-unresponsive model of airway hyperreactivity,
which we reasoned could be utilized to identify novel genes and
pathways that modulate AHR in asthma.
Using this model system, genome-wide expression proﬁling of
the asthmatic lung transcriptome identiﬁed 68 candidate steroid-
unresponsive genes, deﬁned as having a greater than twofold
increase in expression in response toHDMchallenge and remained
greater than twofold increased despite treatment with corticos-
teroids. From these candidate genes,weused real-timequantitative
RT-PCR to conﬁrm that lung mRNA levels of apolipoprotein E
(APOE) were signiﬁcantly increased in HDM-challenged mice
(Yao et al., 2010). Furthermore, APOE mRNA levels remained
greater than twofold elevated in the lungs of HDM-challenged
mice that received corticosteroid treatment as compared to control
mice, thereby identifying APOE as a steroid-unresponsive gene.
Therefore,we hypothesized that apolipoprotein Emightmodulate
the pathogenesis of asthma.
WHY INVESTIGATE THE ROLE OF APOLIPOPROTEIN E IN THE
PATHOGENESIS OF ASTHMA?
Apolipoprotein E (apoE) is a 34-kDa protein that plays a key role in
cholesterol transport and lipoprotein metabolism. An important
function of apolipoprotein E is to facilitate the high-afﬁnity bind-
ing of lipoproteins, such as very low density lipoproteins (VLDL),
a subclass of high density lipoproteins (HDL) and chylomicron
remnants, to the low density lipoprotein (LDL) receptor (Mahley,
1988). Binding of lipoprotein particles to the LDL receptor facili-
tates the transport of cholesterol into cells via the internalization
of lipoprotein particles. This is termed receptor-mediated endocy-
tosis (Goldstein and Brown, 2009). Consistent with this function,
elevations in plasma cholesterol levels are seen in individuals who
lack either apoE (familial apoE deﬁciency) or have genetic defects
in the LDL receptor (familial hypercholesterolemia; Schaefer et al.,
1986; Goldstein and Brown, 2009; Pendse et al., 2009).
Apolipoprotein E is synthesized by most organs, including
the lung. Macrophages, including CD68+ alveolar macrophages,
express apoE (Mahley, 1988; Yao et al., 2010). Apolipoprotein E
has been shown to modulate lung development in mice, as apoE
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knockout mice have diminished developmental alveologenesis,
high airways resistance and more rapid loss of lung recoil with
aging (Massaro and Massaro, 2008).
In the liver, hepatic parenchymal cells are the primary cellular
source of apoE, where it is secreted as a component of VLDL
particles (Mahley, 1988). ApoE is also expressed by astrocytes
in the brain and is found in cerebrospinal ﬂuid, as well as in
smooth muscle cells where it may modulate cellular proliferation
and differentiation (Mahley, 1988). Alveolar type I cells in the rat
have also been reported to express apolipoprotein E (Chen et al.,
2006).
Although the primary function of apoE is to facilitate lipid
transport into cells by receptor-mediated endocytosis mediated
by the LDL receptor, it is has been recognized that apoE modu-
lates a variety of additional important biological functions. The
human APOE gene has three common polymorphic alleles that
result in proteins that have different amino acid sequences at two
sites. ApoE3 has a cysteine at amino acid 112 and an arginine at
amino acid 158, whereas apoE2 has cysteines at both sites while
apoE4 has arginines at both sites (Mahley et al., 2009). ε3 is the
most frequent APOE allele (65–70%), while ε2 (5–10%) and ε4
(15–20%) are less common. The APOE ε4 allele has been identi-
ﬁed a major genetic risk factor for the development of late-onset
Alzheimer’s disease (AD) via its role inmodulating the production,
clearance or aggregation of amyloid-β peptides or, alternatively, by
directly modulating lipid metabolism in the brain or by regulating
synaptic plasticity or repair (Bu, 2009). The APOE ε4 allele has
also been implicated as a risk factor for other neurological disor-
ders, including Parkinson’s disease and multiple sclerosis, which
suggests that it may facilitate accelerated neurodegeneration (Bu,
2009; Mahley et al., 2009).
Apolipoprotein E also modulates adaptive immune responses
andhost susceptibility to infection.Apolipoprotein E facilitates the
presentation of lipid antigens to antigen presenting cells, such as
dendritic cells and B cells via a process that involves the endocyto-
sis of apoE–lipid–antigen complexes via the LDLR (van den Elzen
et al., 2005; Allan et al., 2009). Individuals with the APOE ε4/ε4
genotype have an accelerated disease course with progression to
death as compared to individuals with the APOE ε3/ε3 genotype
in the setting of human immunodeﬁciency virus (HIV) infection.
In particular, the APOE ε4/ε4 genotype may serve as a determi-
nant of HIV–AIDS progression as a consequence of enhancedHIV
fusion and cell entry (Burt et al., 2008). ApoE is also required for
the assembly of hepatitis C virions (HCV) and subsequent cellular
infection, which occurs via an interaction with the HCV non-
structural protein, 5A (NS5A; Chang et al., 2007; Cun et al., 2010).
ApoE has also been implicated in modulating the pathogenesis
of ocular infections caused by herpes simplex virus-1 (Hill et al.,
2007).
APOLIPOPROTEIN E FUNCTIONS AS AN ENDOGENOUS
NEGATIVE REGULATOR OF AIRWAY HYPERREACTIVITY AND
GOBLET CELL HYPERPLASIA IN EXPERIMENTAL HOUSE
DUST MITE-INDUCED ASTHMA
Based upon the ﬁnding that apolipoprotein E has multiple func-
tions, we hypothesized that it may modulate the pathogenesis
or disease severity in asthma. To investigate the role of apoE
in asthma, we compared the asthmatic phenotype of HDM-
challenged apoE knockout mice (apoE−/−) with that of wild-type
mice (Yao et al., 2010). Experimental asthma was induced by nasal
administration of HDM (25μg), 5 days per week for 5weeks.
HDM-challenged apoE−/− had signiﬁcant increases in both AHR,
goblet cell hyperplasia, and mRNA levels of the MUC5AC mucin
gene and CLCA3 (Gob-5), a calcium-activated chloride channel
that has been implicated in the development of goblet cell hyper-
plasia and mucus production (Long et al., 2006). This demon-
strates that apolipoprotein E functions as an endogenous negative
regulator of airway hyperreactivity and goblet cell hyperplasia in
experimental HDM-induced asthma.
We next investigated whether the LDL receptor, which is the
major receptor for apoE, is required for apoE to negatively reg-
ulate AHR and goblet cell hyperplasia in experimental HDM-
induced asthma (Yao et al., 2010). We used confocal immuno-
ﬂuorescence microscopy to demonstrate that the LDL recep-
tor is expressed on ciliated airway epithelial cells where it may
interact with apoE that is released from alveolar macrophages.
Next, we hypothesized that if the LDL receptor functions as
the relevant receptor in the lung for apoE, then the phenotype
of HDM-challenged LDLR−/− mice should recapitulate that of
HDM-challenged apoE−/− mice. Consistent with this hypothe-
sis, we found that HDM-challenged LDLR−/− mice had a phe-
notype of enhanced AHR and goblet cell hyperplasia. Interest-
ingly, type 2 rhinovirus has also been found to bind to LDL
receptors expressed by human tracheal epithelial cells, which up-
regulates the expression of both pro-inﬂammatory cytokines and
the LDL receptor (Suzuki et al., 2001). This suggests a potential
role for LDL receptors in the regulation of airway inﬂammatory
responses to viral infections, which are the most common envi-
ronmental trigger for asthma exacerbations (Wark and Gibson,
2006).
THE THERAPEUTIC POTENTIAL OF APOLIPOPROTEIN E
MIMETIC PEPTIDES
The ﬁnding that apoE functions as an endogenous negative regula-
tor of airway hyperreactivity and goblet cell hyperplasia, suggested
that apoE-mimetic peptides might be utilized experimentally to
rescue the phenotype of HDM-challenged apoE−/− mice. Fur-
thermore, we hypothesized that apoE-mimetic peptides might be
considered as a new asthma therapy that targets a pathway that
is distinct from current asthma treatments. The development of
apoE-mimetic peptides for treatment of disease has its origins in
research aimed at deﬁning the biology of APOE genotypes, which
are best known to alter the course and severity of AD (Corder et al.,
1993). The precise mechanism by which proteins encoded by the
APOE4 gene increase susceptibility to inﬂammation is being stud-
ied. Part of the challenge is to understandwhether theAPOE4 gene
and its apoE4 protein products are providing a dominant gain of
negative function or, alternatively, that they represent the disease-
associated loss of a protective function. Human clinical data shows
heterozygous APOE3/4 patients have onset of disease and severi-
ties of AD that are intermediate between the most severeAPOE4/4
homozygous patients and those with homozygousAPOE3/3 geno-
types (Corder et al., 1993). Since these ﬁndings are consistent with
either gain of negative functions or loss of protective functions, we
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employed APOE knockout mice and transgenic, targeted replace-
ment mice in which the protein-encoding exons for the mouse
apoE gene were replaced with those encoding human APOE3
or human APOE4 genes as tools to decipher the inﬂuence of
apolipoprotein E protein isoforms on inﬂammation (Lynch et al.,
2003). Using LPS treatment of peritoneal macrophages to stimu-
late release of TNF as a biomarker of inﬂammation, we found that
cells from APOE4/4 animals had signiﬁcantly greater TNF levels
than their APOE3/3 counterparts. However, the TNF levels from
APOE 0/0 (knockout) macrophages were not signiﬁcantly differ-
ent from APOE4/4 TNF levels. These ﬁndings suggest that apoE4
proteins had signiﬁcantly reduced abilities to suppress inﬂam-
mation. To further characterize these anti-inﬂammatory activities
of apoE proteins, we mated APOE3/3 and APOE0/0 (knockout)
mice to generate APOE3/0 heterozygous mice and found their
LPS-stimulated TNF levels to be intermediate between those from
APOE3/3 and APOE4/4 mice. This ﬁnding strongly supports the
concept that the apoE3 protein directly functions as an anti-
inﬂammatory agent, that the anti-inﬂammatory effect depends
upon the concentration of apoE protein available, and that the
apoE4 protein is a much less potent anti-inﬂammatory agent.
The development of apoE-mimetic peptides was initially dri-
ven by early studies that mapped the region necessary for
receptor-binding to residues 130–160 of the holo-apoE-protein
(Lalazar et al., 1988; Mahley et al., 2009). Reasoning that pep-
tides spanning this region might also bind to apoE recep-
tors, peptides were synthesized that corresponded to residues
130–149 of the holo-apoE protein (aka. COG130= acetyl-
TEELRVRLASHLRKLRKRLL-amide; Figure 1; Laskowitz et al.,
2001). Similar to the holo-apoE protein, COG130 and COG133,
an amino-terminally truncated peptide spanning residues 133–
149 (acetyl-LRVRLASHLRKLRKRLL-amide), displayed signiﬁ-
cant anti-inﬂammatory activity as measured by reduced TNF
release from LPS-stimulated BV2 microglial cells. Subsequent
studies showed that intravenous administration of COG133 sig-
niﬁcantly reduced TNF and IL-6 levels in the blood and brains
of LPS-stimulated wild-type mice (Lynch et al., 2003). More
recent unpublished studies show that COG133 reduces TNF
release in wild-type (mouse apoE alone), APOE0/0 (knockout)
mice, transgenic replacement APOE3/3 and APOE4/4 mice. From
these results, we hypothesized that holo-apoE proteins and apoE-
mimetic peptides, such as COG133, must stimulate an anti-
inﬂammatorymechanismwithinmacrophages and other cells that
display apoE receptors.
To deﬁne the mechanism of this anti-inﬂammatory action, we
performed a series of studies aimed at ﬁnding binding partners for
apoE and apoE-mimetic peptides (Christensen et al., 2011).While
it is well known that the holo-apoE protein and COG130 can bind
to one or more of a family of structurally related apoE recep-
tor proteins and extracellular matrix molecules, no studies have
reported intracellular binding partners for them. To ﬁnd these
binding partners, we modiﬁed COG133 to contain an amino-
terminal biotin moiety and used this biotinylated-COG133 as a
hook to catch proteins that bound to the biotin–apoE–mimetic
peptide. After addition of biotin-COG133 to mouse microglial
BV2 cells for 30min, lysates containing putative COG133-binding
protein complexes were isolated by afﬁnity chromatography on
streptavidin–agarose columns. After extensive washing of the col-
umn, the resin with bound peptides and protein complexes was
boiled in Laemmli sample buffer and electrophoresed on poly-
acrylamide gels. Silver staining revealed two distinct proteins that
eluted from the resin that were submitted for characterization by
mass spectrometry (ms). Results of the ms/ms characterization
were compared to the protein database and a match was found
with the protein known as SET, which is also known as inhibitor
number 2 of protein phosphatase 2A (I2PP2A). Additional afﬁnity
puriﬁcations followed byWestern blotting showed that the 39- and
25-kDa proteins were immunoreactive with antibodies directed to
the SET protein. Similar binding studies showed that recombi-
nant SET and puriﬁed holo-apoE also co-immunoprecipitated.
Based upon these results, we hypothesized that COG133 could
bind andantagonize SET, therebypermitting re-activationof PP2A
to increase cellular phosphatase activity levels. Proof supporting
this hypothesis was shown by measurements of phosphorylated-
p38MAP kinase (p-p38) where levels of p-p38 increased with LPS
treatments, but then decreased with LPS plus COG133 treatments.
Since LPS-mediated activation of toll-Like receptor 4 (TLR4) leads
to increased cellular levels of p-p38 and eventually to increased
release of TNFandnitric oxide,COG133-mediated reductionof p-
p38 levels should lead to decreased levels of TNF and nitric oxide,
a result which was experimentally veriﬁed in numerous cell-based
and whole animal studies (unpublished observation; Christensen
et al., 2011). These data support a novel mechanism where apoE-
mimetic peptides or holo-apoE bind to SET, thereby permitting
reactivation of PP2A that then leads to decreased signal transduc-
tion in pathways associated with generation of an inﬂammatory
response.
ADMINISTRATION OF AN APOLIPOPROTEIN E MIMETIC
PEPTIDE ATTENUATES THE INDUCTION OF EXPERIMENTAL
HOUSE DUST MITE-INDUCED ASTHMA
Based upon the anti-inﬂammatory properties of apoE-mimetic
peptides, we hypothesized that they might be utilized to mod-
ify disease severity in asthma. Furthermore, we reasoned that
apoE-mimetic peptides could be used to rescue the phenotype
of enhanced airway hyperreactivity and goblet cell hyperplasia
in HDM-challenged apoE−/− mice and thereby conﬁrm the role
of apoE in the pathogenesis of asthma. We elected to utilize
an apoE(130–149) mimetic peptide that corresponded to amino
acids 130–149 of the LDL receptor-binding domain of the native
apoE holoprotein. Systemic administration of the apoE(130–149)
mimetic peptide coincident with daily nasal HDM challenges
successfully attenuated the increased AHR and goblet cell hyper-
plasia, as well as the increased expression of MUC5AC andCLCA3
genes (Yao et al., 2010). Furthermore, systemic administration
of the apoE(130–149) mimetic peptide also attenuated multiple
indices of airway inﬂammation, such as bronchoalveolar lavage
ﬂuid eosinophilia, total serum IgE levels, and mRNA levels of Th2
(IL-4, IL-13) and Th17 (IL-17A) cytokines, as well as chemokines
for eosinophils (CCL7, CCL11, and CCL17). Expression of prod-
ucts of alternatively activatedmacrophages, such as chitinase 3-like
3, arginase 1, and Fizz1 (resistin-like α) were also reduced.
In addition, we reasoned that if apoE negatively regulates
HDM-induced increases in AHR and goblet cell hyperplasia via
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FIGURE 1 | Structure of apolipoprotein E and apoE-mimetic peptides.
Mature holo-apoE is a 299 amino acid protein with polymorphisms at residues
112 and 158 that deﬁne the different protein isotypes: apoE2 (cys112, cys158),
apoE3 (cys112, arg158), and apoE4 (arg112, arg158). The LDL receptor-binding
domain includes residues 130–160. ApoE-mimetic peptides derive from the
region including amino acids 130–150 as shown by the ﬁlled box. The hatched
box extends past the thrombin cleavage site at position 191 to the beginning
of the lipid-binding domain at position 215. The amino-terminal portion
through residues 1–191 forms a 4-helix anti-parallel bundle followed by a
hinge region that extends to residue 215. The carboxy terminal region from
215 to 299 deﬁnes the largely unstructured lipid-binding domain with a major
lipid-binding region from residues 244 to 272. The apoE-mimetic peptide
spanning residues 130–149 is also known as COG130, while the peptide
spanning residues 133–149 is also known as COG133.
the LDL receptor, then HDM-challenged LDLR−/− mice should
be resistant to rescue by the apoE(130–149) mimetic peptide.
Consistent with this, systemic administration of the apoE(130–
149) mimetic peptide to HDM-challenged LDLR−/− mice did
not attenuate AHR, airway inﬂammation or goblet cell hyper-
plasia (Yao et al., 2010). Therefore, we showed that systemic
administration of the apoE(130–149) mimetic peptide attenu-
ated airway inﬂammation, AHR and goblet cell hyperplasia in
HDM-challenged apoE−/−, but not LDLR−/− mice, which is con-
sistent with the conclusion that the effects of apoE in murine
HDM-induced experimental asthma are mediated via the LDL
receptor.
These ﬁndings demonstrate that an apoE – LDL receptor path-
way in the lung functions as an endogenous negative regulator
of HDM-induced airway hyperreactivity and goblet cell hyper-
plasia in a murine model of experimental asthma (Yao et al.,
2010). Lung apoE mRNA levels are increased following HDM
challenge and remain persistently elevated despite corticosteroid
treatment (Yao et al., 2010). Apolipoprotein E may be released
from alveolar macrophages into epithelial lining ﬂuid, where it
can interact with LDL receptors, which are expressed by airway
epithelial cells, to attenuate airway hyperreactivity and goblet
cell hyperplasia (Figure 2). Our laboratory is currently actively
investigating the mechanism by which this is mediated. Further-
more, administration of an apoE-mimetic peptide [apoE(130–
149)] to HDM-challenged apoE−/− mice not only rescued the
phenotype of enhanced AHR and goblet cell hyperplasia, but
also attenuated the induction of HDM-induced eosinophilic air-
way inﬂammation. This suggests that the apoE – LDL receptor
pathway represents a novel druggable target for the development
of new treatment approaches for asthma, especially those with
severe disease. This pathway can be activated by administration
of apoE-mimetic peptides that correspond to the LDL receptor-
binding domain of holo-apolipoprotein E. Thus, our data from an
experimentalmurinemodel of HDM-induced asthma support the
concept of developing inhaled apoE-mimetic peptides, such as the
apoE(130–149) peptide, as a potential new therapeutic approach
for asthma.
THE THERAPEUTIC POTENTIAL OF APOLIPOPROTEIN A-I
MIMETIC PEPTIDES
The success of the apoE(130–149)mimetic peptide suggested to us
that apolipoprotein A-I mimetic peptides might be similarly effec-
tive at attenuating the manifestations of asthma. Apolipoprotein
A-I (apoA-I) accounts for approximately 70% of the protein com-
ponent of HDL (Navab et al., 2011). The main function of HDL
is to mediate reverse cholesterol transport out of peripheral cells,
such as macrophages, and thereby protect against atherosclero-
sis (Navab et al., 2011; Osei-Hwedieh et al., 2011). Cholesterol
is transported out of cells via the ATP-binding cassette trans-
porter 1 (ABCA1), as well as ABCG1 and SR-BI (Osei-Hwedieh
et al., 2011). HDL, however, has additional functions in addition
to reverse cholesterol transport, which include anti-inﬂammatory,
anti-oxidant, anti-ﬁbrotic, and anti-thrombotic properties (Navab
et al., 2011). HDL is also protective against the effects of bacterial
LPS and increases nitric oxide production. Consistent with this,
apoA-I has been found to have protective effects in the lung as
apoA-I knockout mice under basal conditions have an increase
in lung inﬂammation, oxidative stress, and collagen deposition as
compared to wild-type mice (Wang et al., 2010).
ApoA-I mimetic peptides have been developed as a thera-
peutic approach based upon their ability to recapitulate the key
biologic functions of holo-apolipoprotein A-I and HDL, which
include cholesterol transport as well as anti-inﬂammatory and
anti-oxidative properties (Navab et al., 2011; Osei-Hwedieh et al.,
2011). ApoA-I mimetic peptides were ﬁrst designed to understand
the structure of apolipoproteins. One of the ﬁrst such peptides
developed, 18A (DWLKAFYDKVAEKLKEAF), was synthesized to
have a similar distribution of polar and hydrophobic amino acids
as apoA-I and was found to form an amphipathic helix, which is
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FIGURE 2 | A proposed model by which endogenous
holo-apolipoprotein E (apoE) and exogenously administered
apolipoprotein E mimetic peptides [e.g., apoE(130–149)] modulate
experimental house dust mite (HDM)-induced asthma (Yao et al.,
2010). Both endogenous apoE, which is produced by lung macrophages,
and an exogenously administered apoE(130–49) mimetic peptide
attenuated airway hyperreactivity and mucous cell metaplasia via an
interaction with low density lipoprotein receptors (LDLR), such as those
expressed by ciliated airway epithelial cells. Although endogenous apoE
did not modulate HDM-induced airway inﬂammation, administration of the
apoE(130–149) mimetic peptide attenuated airway inﬂammation in apoE
knockout mice, but not in LDLR knockout mice, which suggests that the
anti-inﬂammatory effects of the apoE(130–149) mimetic peptide are
mediated via a LDLR-dependent mechanism.
now known to be a common structural motif of apolipoproteins
(Anantharamaiah et al., 1985; Segrest et al., 1994). Apolipopro-
teins typically have a tandem array of amphipathic helices, which
enable them when on the surface of lipoproteins to bind to lipids.
These helices are oriented parallel to the surface of the phospho-
lipid monolayer on lipoproteins, with the hydrophobic side facing
inward toward the lipids, whereas the polar side faces outward
toward the aqueous environment (Segrest et al., 1994). ApoA-
I mimetic peptides were ﬁrst considered as possible therapeutic
agents when it was shown in clinical trials that four to ﬁve weekly
intravenous infusion of the full-length apoA-I protein complexed
with phospholipid, which was designed to simulate the struc-
ture and composition of nascent HDL, can signiﬁcantly reduce
atherosclerotic plaque in patients with acute coronary syndrome
(Nissen et al., 2003; Tardif et al., 2007). One difﬁculty with this
approach, however, is the relatively large doses of apoA-I needed,
approximately 40mg/Kg, which makes this type of treatment pro-
hibitively expensive and has generated interest in the use of short
synthetic apoA-Imimetic peptides as an alternative (Remaley et al.,
2008).
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Besides serving as tools for understanding the structure of
apoA-I, synthetic peptide mimics of apoA-I have also been shown
to share some of the same biological properties of the full-length
protein (D’Souza et al., 2010). One of the best studied apoA-I
mimetic peptides is the 4F peptide (Navab et al., 2002). It is sim-
ilar in sequence to the 18A peptide but contains 4 phenylalanine
substitutions, and hence its name, in its hydrophobic face. Because
of its relatively high hydrophobicity, the increase in phenylala-
nine content was found to increase the ability of this peptide to
bind to oxidized lipids, a known anti-atherogenic function of HDL
(Anantharamaiah et al., 2007). A version of the peptide when syn-
thesized with d-amino acids called D-4F was found to be partially
orally available and to reduce atherosclerosis in animal models
(Navab et al., 2002). Both oral D-4F and an intravenous prepa-
ration of the peptide made with l-amino acids, L4F, have been
tested in Phase I clinical trials and have been shown to be safe,
although there was limited effect on the functional properties of
HDL from the treated patients (Bloedon et al., 2008;Watson et al.,
2011).
The ability of HDL to remove excess cholesterol from periph-
eral cells and deliver it to the liver for excretion by the reverse
cholesterol transport pathway is believed to be one of the main
anti-atherogenic functions of HDL (Kellner-Weibel and de la
Llera-Moya, 2011). This process begins when apoA-I, by act-
ing like a protein detergent, removes phospholipid and choles-
terol from a lipid microdomain in the plasma membrane cre-
ated by the ABCA1 transporter (Nofer and Remaley, 2005). The
ABCA1 transporter is believed to be a phospholipid ﬂippase
and is the defective gene in Tangier disease, which is a disorder
associated with very low HDL-C levels due to the hypercatab-
olism of apoA-I. Normally when apoA-I acquires phospholipid
by the ABCA1 transporter, it becomes too large to be catab-
olized by the kidney and also becomes competent for efﬂux-
ing cholesterol from cells by additional mechanisms, such as by
the ABCG1 transporter and by SR-BI, as well as by a passive
aqueous diffusion process (Kellner-Weibel and de la Llera-Moya,
2011).
Short synthetic peptides containing amphipathic helices can
also promote lipid efﬂux by the ABCA1 transporter (Remaley
et al., 2003). One such peptide is the 5A peptide (Figure 3; Sethi
et al., 2008). It is a bihelical peptide (DWLKAFYDKVAEKLKEAF-
P-DWAKAAYDKAAEKAKEAA); the ﬁrst helix is identical to 18A,
whereas the second helix is a modiﬁed 18A peptide, which
contains 5 alanine substitutions and hence its name. The two
helices are joined together by proline, which confers a beta
turn and is often found between the 10 different helices in
the full-length apoA-I protein. Alanine, which is only slightly
hydrophobic, was substituted for more hydrophobic amino acids
in the hydrophobic face of the second helix of 5A to reduce
its lipid-binding afﬁnity, which increases the speciﬁcity of the
peptide for cholesterol efﬂux by the ABCA1 transporter (Sethi
et al., 2008). The 5A peptide and several other apolipopro-
tein mimetic peptides that promote cholesterol efﬂux are now
actively being investigated as possible therapeutic agents for the
treatment of atherosclerosis (Sethi et al., 2007; Murphy et al.,
2008; Amar et al., 2010; Tabet et al., 2010; Osei-Hwedieh et al.,
2011).
FIGURE 3 | 5AApolipoprotein A-I mimetic peptide.The 5A peptide is a
37 amino acid long bihelical peptide, containing a proline that links two
amphipathic helices. 5 Alanine substitutions are made in the hydrophobic
face of the second helix to reduce its lipid-binding afﬁnity (courtesy of
Alexander Andrianov, Ph.D. and adapted with permission fromYao et al.,
2011b).
THE 5A APOLIPOPROTEIN A-I MIMETIC PEPTIDE
ATTENUATES THE INDUCTION OF EXPERIMENTAL HOUSE
DUST MITE-INDUCED ASTHMA
We hypothesized that the anti-inﬂammatory, anti-oxidant, and
anti-ﬁbrotic properties of apoA-I might be utilized therapeuti-
cally for the treatment of asthma. Therefore, we assessed whether
systemic administration of the 5A apoA-I mimetic peptide could
attenuate the induction of HDM-induced asthma in wild-type
A/J mice. Systemic administration of the 5A apoA-I mimetic
to HDM-challenged wild-type A/J mice inhibited the cardinal
manifestations of asthma, including airway inﬂammation, air-
way remodeling, and airway hyperreactivity (Figure 4; Yao et al.,
2011a). In particular, HDM-challenged mice that received the 5A
apoA-I mimetic peptide had a signiﬁcant reduction in the num-
bers of bronchoalveolar lavage ﬂuid inﬂammatory cells, which
included eosinophils, lymphocytes, and neutrophils, as well as
the number of lung alternatively activated macrophages and the
expression of Th2 (IL-4, IL-5, IL-13) andTh17 (IL-17A) cytokines.
The expression of lung CC chemokines (CCL7, CCL11, CCL17,
and CCL24) that promote T cell and eosinophil chemotaxis were
also reduced. Administration of the 5A apoA-I mimetic peptide
also attenuated airway remodeling responses, including goblet
cell hyperplasia and expression of collagen genes, Cola1a1 and
Col3a1.
D-4F, another amphipathic, α-helical apoA-I mimetic pep-
tide has also been reported to attenuate the manifestations of
ovalbumin (OVA)-induced asthma in an experimental murine
model (Nandedkar et al., 2011). In this study, nasal admin-
istration of the D-4F apoA-I mimetic peptide to treat OVA-
challenged mice decreased airway inﬂammation, as evidenced
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FIGURE 4 | Exogenous administration of the 5A apolipoprotein A-I mimetic peptide attenuates the induction of airway remodeling, airway
hyperreactivity, and airway inflammation in a murine model of house dust mite-induced asthma (Yao et al., 2011a).
by a reduction in bronchoalveolar lavage ﬂuid eosinophils and
eosinophil peroxidase activity. Total serumIgE and levels of plasma
pro-inﬂammatory HDL were decreased in mice that received
D-4F treatment. D-4F also reduced airway hyperreactivity and
airway remodeling responses as indicated by a reduction in peri-
alveolar and peri-vascular collagen deposition. The beneﬁcial
effects of D-4F in experimental OVA-induced asthma may be
mediated by a reduction in oxidative stress (Nandedkar et al.,
2011).
Taken together, the ability of the 5A and D-4F apoA-I mimetic
peptides to attenuate the manifestations of experimental HDM-
and OVA-induced asthma in murine models suggests that admin-
istration of apoA-I mimetic peptides might represent a novel
treatment approach for asthmatic patients.
CAN INHALED APOLIPOPROTEIN MIMETIC PEPTIDES BE
DEVELOPED INTO A NOVEL TREATMENT APPROACH FOR
ASTHMA?
Data generated from pre-clinical murine models suggest that site-
directed delivery of inhaled apoE or apoA-I mimetic peptides
may represent novel therapeutic approaches for asthma. This
concept is based upon the ability of apoE and apoA-I mimetic
peptides to prevent the induction of experimental asthma in
murine models. The effectiveness of this approach, however, will
ultimately require conﬁrmation in future clinical studies of asth-
matic patients, including those with severe disease. Furthermore,
we hypothesize that if efﬁcacious, the beneﬁcial effects of apoE
and apoA-I mimetic peptides might be most helpful for patients
with severe disease, especially if the apoE or apoA-I mimetic pep-
tides can be shown to be synergistic with corticosteroids and
thereby have a steroid-sparing effect, or ideally, permit the dis-
continuation of corticosteroids. For example, administration of
apolipoprotein mimetic peptides might be used synergistically
with corticosteroids to attenuate persistent airway hyperreactiv-
ity, especially when airway hyperreactivity does not respond to
corticosteroid treatment. The clinical setting where this could
be especially relevant is in individuals with a pauci-granulocytic
sub-phenotype of severe asthma, based upon the absence of ele-
vated eosinophils or neutrophils in induced sputum samples.
Patients with a pauci-granulocytic phenotype comprise approx-
imately 35% of severe asthmatics and would be anticipated to
be poorly responsive to the anti-inﬂammatory effects of corticos-
teroids (Simpson et al., 2008). In addition, apolipoproteinmimetic
peptides might also be effective in attenuating the induction of
eosinophilic and/or neutrophilic airway inﬂammation. Establish-
ing whether apoE or apoA-I mimetic peptides are effective for the
treatment of severe asthma or speciﬁc severe asthma phenotypes,
however, will require data from future clinical trials of asthmatic
patients.
Based upon the data generated in our murine studies, we pro-
pose that the apolipoprotein mimetic peptides be investigated in
clinical trials of human subjects to assess its efﬁcacy and safety. Fur-
thermore,we propose that the apolipoproteinmimetic peptides be
administered via an inhalational approach, which has the advan-
tage of directly targeting the peptide to the airway epithelium,
where, in the case of the apoE(130–149) mimetic peptide, may
facilitate its interaction with LDL receptors to thereby attenuate
the pathogenesis of asthma. Similarly, an inhaled apolipoprotein
mimetic peptide would be easy to administer and thereby obviate
the need for alternative treatment options that require either par-
enteral administration or an invasive procedure. If shown to be
safe and efﬁcacious in asthmatic patients, apolipoprotein mimetic
peptides could potentially enter clinical practice as novel treat-
ment for asthma that has a mechanism of action that is distinct
from currently available therapies.
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